Skip to content
value.today

Aditx Therapeutics, Inc.

Total raised
$24 M
4 rounds on record
Latest round
$6 M
Dec 2023
First round on record
Jan 2021
Today
Private
No later event on record

Funding rounds

4 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Aditx Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2023$6 MNo. 4$2 to $10 million

Aditx Therapeutics, Inc.: Raise no. 4, Dec 2023

Investors in this round

1 investor had bought by the notice of Jan 23, 2024: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$6 M of $6 M offered
Smallest investment taken
no minimum stated
What was sold
equity, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$495,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Amro Albanna · Executive Officer, Director · Chief Executive Officer
  • Corinne Pankovcin · Executive Officer · Chief Commercialization Officer
  • Rowena Albanna · Executive Officer · Chief Operating Officer
  • Shahrokh Shabahang · Executive Officer, Director · Chief Innovation Officer
  • Thomas Farley · Executive Officer · Chief Financial Officer
  • Brian Brady · Director
  • Charles Athle Nelson · Director
  • Jeffrey Runge · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • H.C. Wainwright & Co., LLC (CRD 375) · New York, New YorkSold in CA

Signed by Amro Albanna, Chief Executive Officer. Source: SEC Form D, newest notice filed Jan 23, 2024. Read the notice at the SEC.

equitySEC
Sep 2023$10 MNo. 3$10 to $50 million

Aditx Therapeutics, Inc.: Raise no. 3, Sep 2023

Investors in this round

1 investor had bought by the notice of Sep 20, 2023: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$10 M of $10 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$775,000
Finders' fees
none
Paid to its own people
$436,284 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Amro Albanna · Executive Officer, Director · Chief Executive Officer
  • Corinne Pankovcin · Executive Officer · Chief Commercialization Officer
  • Rowena Albanna · Executive Officer · Chief Operating Officer
  • Shahrokh Shabahang · Executive Officer, Director · Chief Innovation Officer
  • Thomas J. Farley · Executive Officer · Chief Financial Officer
  • Brian J. Brady · Director
  • Jeffrey W. Runge · Director
  • Namvar J. Kiaie · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • H.C. Wainwright & Co., LLC (CRD 375) · New York, New YorkSold in NY

Remarks in the notice

  • On the use of proceeds: “Represents payment of voluntarily deferred payroll to executive officers.”

Signed by Amro Albanna, Chief Executive Officer & Director. Source: SEC Form D, newest notice filed Sep 20, 2023. Read the notice at the SEC.

equity, optionsSEC
Aug 2022$2 MNo. 2$2 to $10 million

Aditx Therapeutics, Inc.: Raise no. 2, Aug 2022

Investors in this round

6 investors had bought by the notice of Aug 17, 2022: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $2 M offered; $0 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$70,700
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Amro Albanna · Executive Officer, Director
  • Corinne Pankovcin · Executive Officer
  • Matthew J. Shatzkes · Executive Officer
  • Rowena Albanna · Executive Officer
  • Shahrokh Shabahang · Executive Officer, Director
  • Thomas J. Farley · Executive Officer
  • Brian J. Brady · Director
  • Jeffrey J. Runge · Director
  • Namvar J. Kiaie · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Network 1 Financial Securities, Inc. (CRD 13577) · Red Bank, New JerseySold in all US states
  • Crito Capital LLC (CRD 161724) · Westport, ConnecticutSold in all US states

Signed by Amro Albanna, Chief Executive Officer. Source: SEC Form D, newest notice filed Aug 17, 2022. Read the notice at the SEC.

equity, debt, optionsSEC
Jan 2021$6 MNo. 1$2 to $10 million

Aditx Therapeutics, Inc.: Raise no. 1, Jan 2021

Investors in this round

1 investor had bought by the notice of Jan 26, 2021: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$6 M of $6 M offered
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them, other: Senior Secured Convertible Promissory Note
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$380,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Amro Albanna · Executive Officer, Director · Chief Executive Officer
  • Corinne Pankovcin · Executive Officer · Chief Financial Officer and Secretary
  • Rowena Albanna · Executive Officer · Chief Operating Officer
  • Shahrokh Shabahang · Executive Officer, Director · Chief Innovation Officer
  • Brian E. Brady · Director
  • Jeffrey W. Runge · Director
  • Laura E. Anthony · Director
  • Namvar E. Kiaie · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Dawson James Securities, Inc. (CRD 130645) · Boca Raton, FloridaSold in all US states

Signed by Amro Albanna, Chief Executive Officer. Source: SEC Form D, newest notice filed Jan 26, 2021. Read the notice at the SEC.

debt, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Aditx Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Jan 2024).

    SEC Form D · Jan 2024

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jan 2024

That is all the official record says: Aditx Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Aditx Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 6 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Aditx Therapeutics, Inc.
NameRoleNamed in
Amro AlbannaChief Executive OfficerJan 2024
Corinne PankovcinChief Commercialization OfficerJan 2024
Rowena AlbannaChief Operating OfficerJan 2024
Shahrokh ShabahangChief Innovation OfficerJan 2024
Thomas FarleyChief Financial OfficerJan 2024
Thomas J. FarleyChief Financial OfficerSep 2023
Matthew J. ShatzkesExecutive officerAug 2022
Amro AlbannaChief Executive OfficerJan 2024
Brian BradyDirectorJan 2024
Charles Athle NelsonDirectorJan 2024
Jeffrey RungeDirectorJan 2024
Shahrokh ShabahangChief Innovation OfficerJan 2024
Brian J. BradyDirectorSep 2023
Jeffrey W. RungeDirectorSep 2023
Namvar J. KiaieDirectorSep 2023
Jeffrey J. RungeDirectorAug 2022
Brian E. BradyDirectorJan 2021
Laura E. AnthonyDirectorJan 2021
Namvar E. KiaieDirectorJan 2021